Bausch+Lomb Results Presentation Deck slide image

Bausch+Lomb Results Presentation Deck

Early Stage Launches and Near-term Pipeline Products to Watch ¹ SiHy Daily Lumify® Expansion Opportunities SeeLuma TM Fully Digital Surgical Visualization Platform (3D Microscope) eye TELLIGENCE® Digital Platform IC-8® Apthera ™ MIMSⓇ Minimally Invasive Surgical Procedure NOV03² Product en Vista Envy ™ en Vista® Trifocal IOL en Vista Aspire ™ en Vista® Extended Range Monofocal IOL en Vista Beyond ™ en Vista® Extended Depth of Focus IOL BAUSCH + LOMB Status Launched in ~25 countries Eye Illuminations - Launching this year Launching now in U.S. and Western Europe Beta software testing ongoing. Regulatory assessments complete. Available in select markets across Europe, as well as in Australia, New Zealand and Singapore Entered into exclusive European distribution agreement with Sanoculis FDA accepted NDA in September 2022 Canada, EU and U.S submissions in process US and Canada submitted 1Q23 EU submission planned for 2Q23 Clinical study to begin 3Q23 1. See Slide 1 for further information on forward-looking statements. 2. In 2019, the Company acquired an exclusive license from Novaliq GmbH for the commercialization and development of NOV03 in the United States and Canada. Upcoming Milestone Planned launch of SVS into more countries in 2023; Multi-focal and toric launch expected in 2023-2024 Preservative Free submission expected 2Q23 Allergy submission expected 1Q24 Additional countries expected to follow U.S. commercial release in process U.S launch in process EU launch in process PDUFA date June 28, 2023 Filed in Canada 1Q23 Expect US, EU, Canada launch in 2024 (includes Toric versions and new EyeGility inserter) Expect US and Canada launch 2H23 (includes Toric; new EyeGility inserter to be added in 2024) EU launch expected in 2024 with EyeGility inserter Expect 2025/2026 launch 20
View entire presentation